[시장보고서]펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 시장 규모, 점유율 및 동향 분석 보고서 - 제품별, 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 시장 규모, 점유율 및 동향 분석 보고서 - 제품별, 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides) By Service (Contract Development, Contract Manufacturing), By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869846

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

펩타이드 및 올리고뉴클레오티드 CDMO 시장 요약

세계의 펩타이드 및 올리고뉴클레오티드 CDMO 시장 규모는 2024년에 28억 달러로 평가되었고, 2033년까지 81억 4,000만 달러에 이를 것으로 예측됩니다.

2025-2033년 연평균 복합 성장률(CAGR) 12.75%로 성장할 전망입니다. 이 시장의 성장 요인으로는 복잡하고 표적화된 치료제에 대한 수요 증가, 생물학적 제제 및 핵산 기반의 의약품 개발에 대한 투자 확대, 제약 및 바이오의약품 기업에서의 아웃소싱 동향 증가, 펩타이드 및 올리고뉴클레오티드의 합성 및 전달 기술 발전을 들 수 있습니다.

또한 펩타이드 및 올리고뉴클레오티드는 대사 장애, 암, 유전성 질환 등 폭넓은 질환의 치료에 있어서 가능성을 나타내고 있습니다. 펩타이드 합성, 합성 화학, 올리고뉴클레오티드 제조의 혁신으로 복잡한 분자의 생산 및 설계가 용이해졌습니다. 이에 따라 치료 용도에 있어서 펩타이드 및 올리고뉴클레오티드의 용도가 대폭 확대되고, 이들 분야에 전문적인 지견을 가진 수탁개발제조기관(CDMO)에 대한 수요가 높아지고 있습니다.

게다가, 개인화된 의료에 대한 경향 증가는 맞춤형 펩타이드 및 올리고뉴클레오티드 치료의 필요성을 촉진하고, 이러한 맞춤 치료 요법의 생산 및 개발에 중요한 역할을 하는 CDMO에 대한 수요를 지원합니다. 또한, 유럽의약청(EMA)과 미국 식품의약국(FDA) 등의 규제 기관은 펩타이드 및 올리고뉴클레오티드의 제조 및 개발에 관한 가이드라인의 확립에 정력적으로 임하고 있습니다. 따라서 앞서 언급한 요인이 시장의 수익성이 높은 성장을 지원하는 요인이 되고 있습니다.

지역별 시장 대시보드
세계 지역 시장 현황
시장 규모 및 예측 동향 분석(2021-2033년) :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
- 오만
- 카타르

제8장 경쟁 구도

기업 분류
- 마켓 리더
- 신흥 기업
펩타이드 및 올리고뉴클레오티드 CDMO 시장 점유율 분석(2024년)
기업 프로파일
- PolyPeptide Group
- STA Pharmaceutical Co. Ltd.
- Bachem
- Creative Peptides
- Aurigene Pharmaceutical Services Ltd.
- Merck KGaA
- EUROAPI
- Curia Global, Inc.
- CordenPharma
- Sylentis, SA

AJY

영문 목차

영문목차

Peptide and Oligonucleotide CDMO Market Summary

The global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 12.75% from 2025 to 2033. The market is driven due to increasing demand for complex and targeted therapeutics, growing investment in biologics and nucleic acid-based drug development, rising outsourcing trends among pharmaceutical and biopharmaceutical companies, and advancements in synthesis and delivery technologies for peptides and oligonucleotides.

In addition, oligonucleotides and peptides have shown potential in treating a wide range of ailments, including metabolic disorders, cancer, and genetic diseases. Innovations in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have made it easier to produce and design complex molecules. This has substantially increased the applications of peptides and oligonucleotides in therapeutic usage and thus boosted the demand for contract development and manufacturing organizations (CDMOs) with specialized proficiency in these areas.

Furthermore, the rising trend toward personalized medicine has driven the need for customized peptide and oligonucleotide therapies, thereby supporting the demand for CDMOs that are vital in the production and development of these personalized treatment therapies. Moreover, regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have diligently worked on establishing guidelines for the manufacturing and development of oligonucleotides and peptides. Hence, the aforementioned factors are responsible for the lucrative growth of the market.

Global Peptide And Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide and oligonucleotide CDMO market report based on product, service, end use, and region.

Product Outlook (Revenue, USD Million, 2021 - 2033)
Peptides
Oligonucleotides
Service Outlook (Revenue, USD Million, 2021 - 2033)
Contract Development
Contract Manufacturing
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical Companies
Biopharmaceutical Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights

Chapter 3. Peptide and Oligonucleotide CDMO Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Peptide and Oligonucleotide CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Supply Chain Analysis
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Peptide and Oligonucleotide CDMO Market Product Movement Analysis
4.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Peptides
- 4.4.1. Peptides Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Oligonucleotides
- 4.5.1. Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Peptide and Oligonucleotide CDMO Market Service Movement Analysis
5.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
5.4. Contract Development
- 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Contract Manufacturing
- 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Peptide and Oligonucleotide CDMO Market End Use Movement Analysis
6.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical Companies
- 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Biopharmaceutical Companies
- 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Competitive Scenario
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Competitive Scenario
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Competitive Scenario
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Competitive Scenario
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. MEA
- 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Competitive Scenario
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Competitive Scenario
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Competitive Scenario
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Competitive Scenario
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.6. Oman
  - 7.8.6.1. Key Country Dynamics
  - 7.8.6.2. Competitive Scenario
  - 7.8.6.3. Regulatory Framework
  - 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.7. Qatar
  - 7.8.7.1. Key Country Dynamics
  - 7.8.7.2. Competitive Scenario
  - 7.8.7.3. Regulatory Framework
  - 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
8.2. Peptide and Oligonucleotide CDMO Market Share Analysis, 2024
8.3. Company Profiles
- 8.3.1. PolyPeptide Group
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Product/Service Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. STA Pharmaceutical Co. Ltd.
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Product/Service Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Bachem
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Product/Service Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. Creative Peptides
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Product/Service Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. Aurigene Pharmaceutical Services Ltd.
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Product/Service Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Merck KGaA
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Product/Service Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. EUROAPI
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Product/Service Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. Curia Global, Inc.
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Product/Service Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. CordenPharma
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Product/Service Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. Sylentis, S.A.
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Product/Service Benchmarking
  - 8.3.10.4. Strategic Initiatives

한글목차

펩타이드 및 올리고뉴클레오티드 CDMO 시장 요약

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 변수, 동향 및 범위

제4장 펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 제품별 추정 및 동향 분석

제5장 펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 서비스별 추정 및 동향 분석

제6장 펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 최종 용도별 추정 및 동향 분석

제7장 펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 제품, 서비스, 최종 용도별 지역별 추정 및 동향 분석